HK1008981A1 - Cosmetic composition containing a neuropeptide y receptor antagonist. - Google Patents

Cosmetic composition containing a neuropeptide y receptor antagonist.

Info

Publication number
HK1008981A1
HK1008981A1 HK98109761A HK98109761A HK1008981A1 HK 1008981 A1 HK1008981 A1 HK 1008981A1 HK 98109761 A HK98109761 A HK 98109761A HK 98109761 A HK98109761 A HK 98109761A HK 1008981 A1 HK1008981 A1 HK 1008981A1
Authority
HK
Hong Kong
Prior art keywords
neuropeptide
composition containing
cosmetic composition
receptor antagonist
antagonist
Prior art date
Application number
HK98109761A
Other languages
English (en)
Inventor
Elisabeth Blanc-Ferras
Francoise Bono
Bernard Breda
Jean Courregelongue
Catherine Ducasse
Remy Mounier
Paul Raymond
Jean-Marie Pereillo
Michel Sabadie
Claudine Serradeil-Le-Gal
Pol Vilain
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HK1008981A1 publication Critical patent/HK1008981A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P11/00—Preparation of sulfur-containing organic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
    • C12P7/26—Ketones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2323/00—Functional layers of liquid crystal optical display excluding electroactive liquid crystal layer characterised by chemical composition
    • C09K2323/06—Substrate layer characterised by chemical composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C12R2001/10—Bacillus licheniformis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK98109761A 1996-10-23 1998-08-07 Cosmetic composition containing a neuropeptide y receptor antagonist. HK1008981A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9612916A FR2754709B1 (fr) 1996-10-23 1996-10-23 Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition

Publications (1)

Publication Number Publication Date
HK1008981A1 true HK1008981A1 (en) 1999-05-21

Family

ID=9496938

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98109761A HK1008981A1 (en) 1996-10-23 1998-08-07 Cosmetic composition containing a neuropeptide y receptor antagonist.

Country Status (23)

Country Link
US (3) US5827853A (zh)
EP (3) EP1132463B1 (zh)
JP (1) JP3411463B2 (zh)
KR (1) KR100240143B1 (zh)
CN (1) CN1214780C (zh)
AR (1) AR005583A1 (zh)
AT (3) ATE230974T1 (zh)
AU (1) AU705046B2 (zh)
BR (1) BR9700835A (zh)
CA (1) CA2196096C (zh)
CO (1) CO4780017A1 (zh)
DE (3) DE69718409T2 (zh)
ES (3) ES2316403T3 (zh)
FR (1) FR2754709B1 (zh)
HK (1) HK1008981A1 (zh)
HU (1) HU222663B1 (zh)
IL (1) IL120092A (zh)
MX (1) MX9700822A (zh)
MY (1) MY117993A (zh)
PE (1) PE799A1 (zh)
PT (2) PT1093803E (zh)
SI (3) SI1093803T1 (zh)
TW (1) TW434024B (zh)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US8466109B2 (en) * 1998-10-05 2013-06-18 Laboratoires Expanscience Cosmetic method for preventing and/or treating skin stretchmarks, and use in dermatology
FR2787712B1 (fr) * 1998-12-24 2002-08-30 Sanofi Sa Composition cosmetique pulverisable et matrice utilisable dans cette composition pour une administration dermique
US6375948B1 (en) 1999-07-12 2002-04-23 Kao Corporation Treating method for suppressing hair growth
FR2800610B1 (fr) * 1999-11-05 2001-12-28 Sanofi Synthelabo Composition cosmetique amincissante contenant une substance inducteur de la production d'il-6
US20040053864A1 (en) * 2000-01-20 2004-03-18 Gerard Karsenty Methods and compositions for control of bone formation via modulation of neuropeptide y activity
WO2002028393A1 (en) * 2000-10-03 2002-04-11 The Regents Of The University Of California Use of neuropeptide-y antagonists in treatment of alcoholism
US7069026B2 (en) * 2001-06-28 2006-06-27 Nokia Corporation Geographic area assisted system selection for mobile stations
WO2003009854A1 (en) * 2001-07-20 2003-02-06 Lonza Ag Lipid lowering composition comprising carnitine and phytosterol
US20060165683A1 (en) 2001-12-05 2006-07-27 Gerard Karsenty Methods and compositions for control of bone formation via modulation of sympathetic tone
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
FR2853541B1 (fr) * 2003-04-09 2008-07-04 Oreal Composition cosmetique stable contenant un glyceride d'acides gras, un alcool et un emulsionnant silicone particulier
US7371871B2 (en) 2003-05-05 2008-05-13 Probiodrug Ag Inhibitors of glutaminyl cyclase
DE10340417C5 (de) * 2003-09-02 2011-05-05 Sebapharma Gmbh & Co. Kg Kosmetische oder dermatologische Zubereitung mit Phytosterolen in Form einer W/O-Emulsion
US20050137142A1 (en) 2003-11-03 2005-06-23 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
KR101099206B1 (ko) 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
CA2570210C (en) * 2004-06-15 2013-01-08 The Boots Company Plc Hair growth compositions comprising centella asiatica and green coffee extracts
FR2871688B1 (fr) 2004-06-16 2008-05-16 Oreal Procede pour favoriser la penetration d'un actif et composition permettant sa mise en oeuvre
AU2006235200A1 (en) * 2005-04-15 2006-10-19 Regenertech Pty Limited Use of Neuropeptide Y (NPY) and agonists and antagonists thereof for tissue regeneration
WO2006133160A2 (en) * 2005-06-06 2006-12-14 Georgetown University Compositions and methods for lipo modeling
US8074496B2 (en) * 2005-06-24 2011-12-13 Marco Brandestini Apparatus for hardness measurement by impact
FR2895239B1 (fr) * 2005-12-22 2008-05-30 Oreal Utilisation d'un antagoniste du neuropeptide y pour le soin des levres endommagees ou sensibles
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP1970051A1 (en) * 2007-03-14 2008-09-17 Merz Pharma GmbH & Co.KGaA Use of an aqueous micro-emulsion for the preparation of a formulation for the treatment of adipose diseases
MX2009009234A (es) 2007-03-01 2009-12-01 Probiodrug Ag Uso nuevo de inhibidores de ciclasa de glutaminilo.
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
GB0719545D0 (en) * 2007-10-08 2007-11-14 Barry Callebaut Ag Novel use of cocoa extract
GB0719542D0 (en) * 2007-10-08 2007-11-14 Barry Callebaut Ag Use of cocoa extract
GB0719544D0 (en) * 2007-10-08 2007-11-14 Barry Callebaut Ag Cocoa extract and use thereof
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
JOP20180077A1 (ar) * 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc تركيبات وطرق لحمض صفراوي تخليقي
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
JO3172B1 (ar) * 2007-06-19 2018-03-08 Kythera Biopharmaceuticals Inc تركيبة وطريقة وتحضير الصفراء الصناعية
US20090263518A1 (en) 2008-04-17 2009-10-22 Barry Callebaut Ag Composition and Uses Thereof
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US20100233301A1 (en) * 2009-03-11 2010-09-16 Jing Cheng Topical compositions comprising fermented extracts of traditional chinese medicinal (tcm) ingredients, and methods of making and using same
EA022007B1 (ru) 2009-09-11 2015-10-30 Пробиодруг Аг Гетероциклические производные в качестве ингибиторов глутаминилциклазы
FR2953716B1 (fr) 2009-12-16 2015-03-27 Oreal Kit de formulation d'un produit cosmetique
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
BR112013003216A2 (pt) 2010-08-12 2016-05-17 Kythera Biopharmaceuticals Inc composições sintéticas de ácido biliar e métodos
FR2967573B1 (fr) 2010-11-23 2012-11-09 Rhodia Poliamida E Especialidades Ltda Kit cosmetique et utilisation pour ameliorer l'aspect de la peau
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
EP2735310B1 (en) 2011-08-23 2017-10-11 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
CN108619089A (zh) 2011-08-23 2018-10-09 凯瑟拉生物制药有限公司 脱氧胆酸和其盐的制剂
WO2013060771A2 (en) * 2011-10-25 2013-05-02 Arch Personal Care Products, L.P. Composition containing an extract of a sequential or simultaneous fermentation
JP6300641B2 (ja) * 2014-05-30 2018-03-28 ワミレスコスメティックス株式会社 皮膚バリア機能改善効果を有する放線菌培養物
CA3003746A1 (en) 2015-11-04 2017-05-11 Kythera Biopharmaceuticals, Inc. Treatments of accumulated fat with deoxycholic acid and salts thereof
JP6938860B2 (ja) * 2016-06-13 2021-09-22 株式会社リコー 形状支持用液体、及び立体造形物の製造方法
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2979511A (en) 1959-03-25 1961-04-11 Olin Mathieson Certain 1, 4-benzodioxanyl imidazolines and corresponding pyrimidines and process
DE2603407A1 (de) 1976-01-29 1977-08-04 Wmf Wuerttemberg Metallwaren Wasserkessel
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4337260A (en) 1981-09-10 1982-06-29 Yoshitomi Pharmaceutical Industries, Ltd. Imidazopyridine-spiro-piperidine compounds
JPS59192086A (ja) * 1983-04-15 1984-10-31 Mitsui Toatsu Chem Inc バチルス・リケニホルミスｍｎ００１
GB2138023A (en) * 1983-03-29 1984-10-17 Mitsui Toatsu Chemicals Bacillus licheniformis used in animal feeds
DE3410033A1 (de) 1984-03-19 1985-09-26 Alfred Teves Gmbh, 6000 Frankfurt Vorrichtung zur hydraulischen unterstuetzung der lenkkraft
US5128332A (en) * 1984-10-23 1992-07-07 Perstorp Ab Method of treating cardiovascular diseases using inositoltrisphosphate
GB2167408B (en) 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
JPS61155317A (ja) * 1984-12-28 1986-07-15 Lion Corp 口腔用組成物
DE3545986A1 (de) * 1985-12-23 1987-06-25 Franz Sauter Elektronisch gesteuertes musikinstrument
JPH01502340A (ja) * 1987-02-24 1989-08-17 インスティテュト　ミクロビオロギイ　イ　ビルソロギイ　イメニ　デー．カー．ザボロトノゴ　アカデミイ　ナウク　ウクラインスコイ　エスエスエル 家畜の胃腸病の予防及び処置のための製剤
DE3811193A1 (de) 1988-04-01 1989-10-19 Boehringer Ingelheim Kg Neue peptide, verfahren zu ihrer herstellung und diese peptide enthaltende pharmazeutische zusammensetzungen
US5328899A (en) 1988-07-15 1994-07-12 The Salk Institute For Biological Studies NPY peptide analogs
EP0356399A3 (en) * 1988-08-26 1991-03-20 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
ZA896374B (en) 1988-08-26 1990-05-30 Merrell Dow Pharma Neuropeptide y antagonists
US5116605A (en) * 1989-03-09 1992-05-26 Alt John P Composition and skin treatment method therewith for mitigating acne and male-pattern baldness
DE59006842D1 (de) 1990-03-30 1994-09-22 Heumann Pharma Gmbh & Co Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung.
SE9002278L (sv) 1990-06-28 1991-12-29 Perstorp Ab Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel
SE467340B (sv) * 1990-07-04 1992-07-06 Perstorp Ab Anvaendning av inositolmonofosfat foer framstaellning av ett laekemedel effektivt som en neuropeptid y-(npy-)antagonist
FR2669537B1 (fr) * 1990-11-28 1993-02-19 Oreal Composition amincissante a base d'alpha-2-bloqueurs.
TW263508B (zh) 1991-02-12 1995-11-21 Pfizer
CA2126212A1 (en) 1991-12-19 1993-07-08 Albert Tseng A novel molecule which inhibits neuropeptide tyrosine biological function
GB9213215D0 (en) 1992-06-20 1992-08-05 Wellcome Found Peptides
DE4326465A1 (de) 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
FR2701480B1 (fr) 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
DE4311756A1 (de) 1993-04-08 1994-10-13 Thomae Gmbh Dr K Modifizierte Peptide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0707490A1 (en) 1993-06-18 1996-04-24 University Of Cincinnati Neuropeptide y antagonists and agonists
JPH07258068A (ja) * 1994-03-18 1995-10-09 Kao Corp 浴用剤組成物
JP3447809B2 (ja) * 1994-07-12 2003-09-16 花王株式会社 浴用剤
EP0705807B1 (en) * 1994-10-06 1999-09-01 Susumu Hibino Bacterial preparation for agricultural use
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
AU3953795A (en) 1994-10-20 1996-05-15 Eli Lilly And Company Bicyclic neuropeptide y receptor antagonists
CA2203878C (en) * 1994-11-07 2002-06-25 John M. Peterson Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US5621079A (en) * 1995-02-03 1997-04-15 Merck & Co., Inc. Neuropeptide Y receptor
US5536499A (en) * 1995-02-24 1996-07-16 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions for reducing or preventing signs of cellulite
US5552411A (en) 1995-05-26 1996-09-03 Warner-Lambert Company Sulfonylquinolines as central nervous system and cardiovascular agents
US5552148A (en) * 1995-06-07 1996-09-03 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Petroleum jelly with inositol phosphates
US5554621A (en) 1995-06-07 1996-09-10 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives
US5646151A (en) * 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
FR2787712B1 (fr) * 1998-12-24 2002-08-30 Sanofi Sa Composition cosmetique pulverisable et matrice utilisable dans cette composition pour une administration dermique
FR2788434B1 (fr) * 1999-01-15 2001-05-11 Oreal Utilisation d'au moins un extrait d'au moins une bacterie filamenteuse non photosynthetique en tant qu'agent amincissant

Also Published As

Publication number Publication date
US6313128B1 (en) 2001-11-06
HU222663B1 (hu) 2003-09-29
CO4780017A1 (es) 1999-05-26
ATE408396T1 (de) 2008-10-15
CA2196096C (en) 2001-10-23
EP1093803A3 (fr) 2004-03-31
PE799A1 (es) 1999-04-08
FR2754709B1 (fr) 1999-03-05
BR9700835A (pt) 1998-07-07
HUP9700410A3 (en) 1999-07-28
US5827853A (en) 1998-10-27
IL120092A0 (en) 1997-04-15
KR19980032063A (ko) 1998-07-25
FR2754709A1 (fr) 1998-04-24
EP1093803B1 (fr) 2008-09-17
EP1093803A2 (fr) 2001-04-25
JPH10120551A (ja) 1998-05-12
EP0838217B1 (fr) 2003-01-15
HUP9700410A2 (hu) 1998-07-28
PT1132463E (pt) 2009-01-23
TW434024B (en) 2001-05-16
SI1093803T1 (sl) 2009-02-28
IL120092A (en) 2001-08-08
DE69739079D1 (de) 2008-12-11
ES2313914T3 (es) 2009-03-16
ES2191154T3 (es) 2003-09-01
MY117993A (en) 2004-08-30
DE69718409D1 (de) 2003-02-20
ATE230974T1 (de) 2003-02-15
EP1132463A2 (fr) 2001-09-12
CA2196096A1 (en) 1998-04-24
SI0838217T1 (en) 2003-08-31
EP1132463A3 (fr) 2004-03-24
SI1132463T1 (sl) 2009-04-30
JP3411463B2 (ja) 2003-06-03
EP0838217A2 (fr) 1998-04-29
DE69739002D1 (de) 2008-10-30
ATE412399T1 (de) 2008-11-15
KR100240143B1 (ko) 2000-02-01
EP0838217A3 (fr) 1998-10-14
AU1251597A (en) 1998-05-07
CN1180519A (zh) 1998-05-06
PT1093803E (pt) 2008-12-26
AU705046B2 (en) 1999-05-13
AR005583A1 (es) 1999-06-23
DE69718409T2 (de) 2003-11-13
MX9700822A (es) 1998-04-30
HU9700410D0 (en) 1997-03-28
EP1132463B1 (fr) 2008-10-29
ES2316403T3 (es) 2009-04-16
CN1214780C (zh) 2005-08-17
US6114336A (en) 2000-09-05

Similar Documents

Publication Publication Date Title
HK1008981A1 (en) Cosmetic composition containing a neuropeptide y receptor antagonist.
AU7079498A (en) Neuropeptide y receptor antagonist
AU2242197A (en) Benzimidzolyl neuropeptide y receptor antagonists
HU9603525D0 (en) Vironectin receptor antagonists
IL120724A0 (en) Indolyl neuropeptide Y receptor antagonists
ZA953311B (en) Non-peptidyl tachykinin receptor antagonists
HU9601529D0 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists
EP0912175A4 (en) FIBRINOGENIC RECEPTOR ANTAGONISTS
HU9600663D0 (en) Endothelin-receptor antagonists
EP0885205A4 (en) FIBRINOGENIC RECEPTOR ANTAGONISTS
EP0885213A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
AU9185598A (en) Novel neuropeptide y receptor antagonists
EP0809648A4 (en) RECEPTOR FOR THE NEUROPEPTID Y
IL134301A0 (en) 2-acylaminopropanamines as tachykinin receptor antagonists
GB9523999D0 (en) Indolyl neuropeptide y receptor antagonists
GB9600344D0 (en) Benzimidzolyl neuropeptide y receptor antagonists
ZA98256B (en) Tachykinin antagonists
IL134155A0 (en) 2-acylaminopropanamines as tachykinin receptor antagonists
GB2325231B (en) A cosmetic composition
HU9602253D0 (en) Endothelin-receptor antagonists
AU7580998A (en) 3-arylpropylamino neuropeptide y receptor antagonists
AU6826498A (en) Endotholin receptor antagonists
GB9708766D0 (en) Fibrinogen receptor antagonist
EP0957908A4 (en) FIBRINOGENIC RECEPTOR ANTAGONISTS
AUPO733697A0 (en) Neuropeptide y-y7 receptor

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140314